VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- May 11, 2007 -- Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that Dr. Anthony Tolcher, Director of Clinical Research at START (South Texas Accelerated Research Therapeutics), has joined its oncology Clinical Advisory Board. Comprised of leading oncologists and translational researchers, Chemokine's advisory boards play an important role in guiding and participating in Chemokine's clinical development programs.
